Company lawyers spent yesterday working with market access and leadership teams on how to respond to the Department of Health and the breach of confidentiality on special pricing arrangements.

Latest Video
New Stories
-
OncoSil Medical completes recruitment in TRIPP-FFX clinical trial
July 23, 2025 - - Australian Biotech -
Nyrada advances Xolatryp towards Phase 2a trial in cardioprotection
July 23, 2025 - - Australian Biotech -
Amplia Therapeutics announces $25 million placement and launches share purchase plan
July 23, 2025 - - Australian Biotech -
Percheron Therapeutics announces publication of new preclinical HMBD-002 data
July 23, 2025 - - Australian Biotech -
US leads the way on cell and gene therapy with new rapid access program
July 23, 2025 - - Latest News -
Neuraxpharm continues international expansion with launch of Australian affiliate
July 23, 2025 - - Latest News -
Companies secure certification as 'Great Places to Work'
July 23, 2025 - - Latest News